دورية أكاديمية
أعرض في EDS

CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma.
المؤلفون: Cheng J; Xi'an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, 710021, China., Li J; Xi'an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, 710021, China., Jiang X; Xi'an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, 710021, China., Ma X; Xi'an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, 710021, China., Li B; Xi'an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, 710021, China., Zhai H; Xi'an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, 710021, China., Luo X; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361003, P.R. China.; Xiamen Key Laboratory of Otolaryngology Head and Neck Surgery, Xiamen, 361003, China., Zhou Y; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361003, P.R. China.; Xiamen Key Laboratory of Otolaryngology Head and Neck Surgery, Xiamen, 361003, China., Wu J; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361003, P.R. China.; Xiamen Key Laboratory of Otolaryngology Head and Neck Surgery, Xiamen, 361003, China., Zhang Z; Department of Breast Surgery, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361003, P.R. China.; Teaching Hospital of Fujian Medical University, Fuzhou, Fujian, 350004, P.R. China., Chen S; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361003, P.R. China. chenshuai@xmu.edu.cn.; Xiamen Key Laboratory of Otolaryngology Head and Neck Surgery, Xiamen, 361003, China. chenshuai@xmu.edu.cn., Wang Y; Xi'an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, 710021, China. yang.wang@xiyi.edu.cn.
المصدر: Molecular medicine (Cambridge, Mass.) [Mol Med] 2024 Aug 08; Vol. 30 (1), pp. 116. Date of Electronic Publication: 2024 Aug 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 9501023 Publication Model: Electronic Cited Medium: Internet ISSN: 1528-3658 (Electronic) Linking ISSN: 10761551 NLM ISO Abbreviation: Mol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: 2018- : [London, United Kingdom] : BioMed Central
Original Publication: Cambridge, Mass. : Blackwell Scientific Publications, c1994-
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/immunology , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/therapy , Carcinoma, Hepatocellular*/genetics , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/etiology , Tumor Microenvironment*/immunology , Liver Neoplasms*/immunology , Liver Neoplasms*/metabolism , Liver Neoplasms*/pathology , Liver Neoplasms*/genetics , Liver Neoplasms*/therapy , Liver Neoplasms*/etiology , Antigens, Differentiation, B-Lymphocyte*/metabolism , Antigens, Differentiation, B-Lymphocyte*/genetics , Immunotherapy*/methods , Histocompatibility Antigens Class II*/metabolism , Histocompatibility Antigens Class II*/genetics , Histocompatibility Antigens Class II*/immunology, Humans ; Prognosis ; Gene Expression Regulation, Neoplastic ; Biomarkers, Tumor ; Computational Biology/methods
مستخلص: Background: CD74 is ectopically expressed in many tumors and can regulate tumor immunity. However, there are many gaps in the study of the prognostic value of CD74 expression and immune infiltration in hepatocellular carcinoma (HCC).
Methods: An online tumor database was searched to obtain data on gene/protein expression. Immune infiltration analysis was performed using the Tumor Immune Estimation Resource and Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer databases. Single-cell data were obtained from the Tissue-specific Gene Expression and Regulation, Single-cell Transcriptomes of Tumor Immune Microenvironment and Tumor Immune Single-cell Hub 2 databases.
Results: CD74 was highly expressed in HCC patients. HCC patients with high CD74 expression who consumed alcohol or were negative for hepatitis virus had a better prognosis than patients with low CD74 expression. CD74 was mainly enriched in immune response regulation pathways. Both copy number variations in CD74 and CD74 expression patterns affected the infiltration levels of immune cells. Interestingly, CD74 regulated the differentiation of myeloid cells. CD74 in macrophages and dendritic cells (DCs) forms complex networks with malignant cells and hepatic progenitor cell (HPC)-like cells, respectively. High CD74 expression in HPC-like cells and malignant cells significantly decreased the fraction of C-type lectin domain family 9 A (CLEC9A)-cDC1 + DCs and IL-1B + macrophages, respectively. Their crosstalk subsequently shaped the tumor microenvironment of HCC, possibly through the CD74-MIF axis. Importantly, patients with high CD74 expression presented higher immune scores and achieved good outcomes after receiving immunotherapy.
Conclusion: High CD74 expression is associated with the abundance of a variety of immune cell types, mediating interactions among tumor and immune cells and shaping the malignant behavior of HCC. In summary, CD74 may be a hallmark for determining the prognosis and immune cell infiltration levels of HCC patients.
(© 2024. The Author(s).)
References: Annu Rev Immunol. 1994;12:259-93. (PMID: 8011283)
Cancer Cell. 2022 Dec 12;40(12):1583-1599.e10. (PMID: 36423636)
Elife. 2022 Oct 31;11:. (PMID: 36315425)
J Immunol. 2006 Dec 15;177(12):8730-9. (PMID: 17142775)
Front Cardiovasc Med. 2022 Sep 14;9:950961. (PMID: 36186997)
Br J Pharmacol. 2021 Nov;178(22):4452-4467. (PMID: 34250589)
Nat Med. 2018 May;24(5):541-550. (PMID: 29686425)
Oncol Lett. 2018 May;15(5):7631-7638. (PMID: 29731899)
Oncogene. 2016 Dec 1;35(48):6246-6261. (PMID: 27157615)
Endocr Relat Cancer. 2015 Apr;22(2):179-90. (PMID: 25600560)
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188720. (PMID: 35304295)
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6. (PMID: 23420197)
Nat Commun. 2020 Oct 8;11(1):5077. (PMID: 33033240)
Nat Commun. 2022 Dec 7;13(1):7533. (PMID: 36476645)
MedComm (2020). 2023 Mar 05;4(2):e229. (PMID: 36891351)
Mol Cancer. 2021 Dec 13;20(1):164. (PMID: 34903219)
Front Immunol. 2022 Jul 28;13:950536. (PMID: 35967424)
Cancer Immunol Immunother. 2022 Jan;71(1):57-69. (PMID: 34009409)
Cancer Lett. 2022 Dec 28;551:215972. (PMID: 36265653)
Open Access Maced J Med Sci. 2019 Oct 14;7(19):3169-3176. (PMID: 31949511)
Semin Cell Dev Biol. 2015 May;41:39-48. (PMID: 24910448)
Transl Lung Cancer Res. 2018 Dec;7(6):661-667. (PMID: 30505710)
J Hepatol. 2022 Aug;77(2):467-478. (PMID: 35367532)
EMBO J. 2017 Nov 15;36(22):3336-3355. (PMID: 29038174)
Cancer Res. 2021 Jun 1;81(11):3036-3050. (PMID: 33619115)
Front Med. 2018 Aug;12(4):426-439. (PMID: 30097962)
Gut. 2022 Mar;71(3):616-626. (PMID: 33563643)
Expert Opin Ther Targets. 2011 Mar;15(3):237-51. (PMID: 21208136)
Virchows Arch. 2018 Apr;472(4):653-665. (PMID: 29356891)
Inflamm Res. 2017 Mar;66(3):209-216. (PMID: 27752708)
Nat Commun. 2022 Oct 2;13(1):5782. (PMID: 36184646)
Nat Genet. 2022 Dec;54(12):1782-1785. (PMID: 36443443)
J Hematol Oncol. 2021 Jun 9;14(1):91. (PMID: 34108022)
Front Immunol. 2018 May 23;9:1132. (PMID: 29875777)
Mol Cancer. 2021 Oct 11;20(1):131. (PMID: 34635121)
J Pathol Clin Res. 2019 Jan;5(1):12-24. (PMID: 30191677)
Br J Haematol. 2023 Jun;201(5):917-934. (PMID: 36852636)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Cancer Gene Ther. 2023 May;30(5):716-726. (PMID: 36599974)
Hepatology. 2023 Jan 1;77(1):77-91. (PMID: 35567547)
Front Immunol. 2022 Jul 05;13:921900. (PMID: 35865544)
Sci Rep. 2023 Mar 6;13(1):3728. (PMID: 36878930)
Front Cell Dev Biol. 2022 Jun 17;10:914120. (PMID: 35784460)
Cancer Lett. 2021 Jun 28;508:47-58. (PMID: 33766751)
Oncotarget. 2017 Feb 21;8(8):12664-12674. (PMID: 27058619)
معلومات مُعتمدة: 82103189 National Natural Science Foundation of China; 2020J05302 Natural Science Foundation of Fujian Province; 2021J011358 Natural Science Foundation of Fujian Province; 2022J011363 Natural Science Foundation of Fujian Province; 3502Z20227339 Natural Science Foundation of Xiamen Municipality; 2021JQ-780 Natural Science Basic Research Program of Shaanxi Province; 2019-WJ-34 Health Education Joint Project of Fujian Province; 2021GGB026 Science Foundation of the Fujian provincial Commission of Health and Family Planning; 3502Z20244ZD1032 Xiamen medical and health guiding project; 3502720244ZD1012 Xiamen medical and health guiding project
فهرسة مساهمة: Keywords: CD74; Hepatocellular carcinoma; IL-1B+ macrophages; Immune infiltration; Myeloid cells
المشرفين على المادة: 0 (Antigens, Differentiation, B-Lymphocyte)
0 (invariant chain)
0 (Histocompatibility Antigens Class II)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240808 Date Completed: 20240808 Latest Revision: 20240811
رمز التحديث: 20240812
مُعرف محوري في PubMed: PMC11308498
DOI: 10.1186/s10020-024-00884-x
PMID: 39118044
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-3658
DOI:10.1186/s10020-024-00884-x